系统性硬化症相关肌病筛查算法的评估
在澳大利亚硬皮病队列中评估系统性硬化症(SSc)相关肌肉受累的筛查算法:常规诊疗中18.5%患者至少一次出现近端无力、15.8%肌酸激酶(CK)升高,而活检证实肌病仅2.1%;南澳亚组按拟议算法筛查后9.9%接受活检且全部异常,炎症性肌病(IM)检出较常规诊疗提高约4.5倍。
要点
- SSc患者常规诊疗中无力与CK升高常见,但活检证实肌病比例低。
- 按筛查算法(无力/或CK升高→肌炎免疫印迹和/或肌肉MRI→活检)可提高IM检出。
- 活检证实的非炎症性肌病可避免不必要的免疫抑制治疗。
核心结论
- 在筛查的SSc患者中9.9%活检证实肌肉受累,IM检出较常规诊疗增加约4.5倍,使及时治疗成为可能并避免非炎症性肌病的不必要免疫抑制。
研究设计与样本
- 澳大利亚硬皮病队列研究(ASCS)连续SSc患者每年评估近端无力和CK,医师判断决定进一步检查;南澳亚组在无力/或CK升高时加做肌炎免疫印迹和/或肌肉MRI,阳性者行肌肉活检。
主要发现
- 1443例中260/1407(18.5%)至少一次无力、203/1282(15.8%)CK升高(中位随访5.19年);26/1253(2.1%)活检证实肌病,其中1.4%为IM。
- 南澳亚组117/425(27.5%)无力、80/421(19%)CK升高、42/423(9.9%)基于阳性筛查接受活检。
- 42例活检全部异常:28/42(66.7%)为IM、14/42(33.3%)为非特异性肌病性改变;南澳活检证实IM为28/423(6.6%),ASCS队列为18/1253(1.4%)。
- IM促使使用免疫调节治疗,所有病例肌力均有改善。
关键数值与推荐
- 拟议筛查算法:存在无力和/或CK升高时行肌炎免疫印迹和/或肌肉MRI,阳性发现促使肌肉活检。
- 南澳亚组活检依据:无力和/或CK升高(n=48)、肌炎特异性/相关性自身抗体(n=10)或MRI异常(n=8)。
临床怎么用
- 对SSc患者常规监测近端无力和CK,异常者按算法加做肌炎抗体和/或肌肉MRI,阳性者考虑活检以区分IM与非炎症性肌病。
- 确诊IM者及时启动免疫调节治疗;非炎症性肌病则避免不必要的免疫抑制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Prevalence of muscle involvement in systemic sclerosis (SSc) ranges from 6% to 96%. If inflammatory myopathy (IM) is present, early diagnosis enables timely treatment; however, there is no standardized approach to detection. We evaluated a screening algorithm for SSc-related muscle involvement. METHODS: Consecutive SSc patients in the Australian Scleroderma Cohort Study (ASCS) were assessed annually for clinical features of myopathy [proximal weakness and elevated creatine kinase (CK)] during routine care, with further investigations performed according to physician judgement. In a subset of patients from South Australia (SA), if weakness and/or elevated CK was present, further assessment with myositis immunoblot and/or muscle MRI (proposed screening algorithm) was applied; positive findings prompted muscle biopsy. RESULTS: Among 1443 patients, 260/1407 (18.5%) had weakness and 203/1282 (15.8%) an elevated CK at least once during routine care (median follow-up 5.19 years). 26/1253 (2.1%) had biopsy-proven myopathy (1.4% IM). In SA patients, 117/425 (27.5%) had weakness, 80/421 (19%) elevated CK and 42/423 (9.9%) underwent muscle biopsy based on a positive screen [weakness and/or elevated CK (n = 48), myositis-specific/myositis-associated autoantibodies (n = 10) or MRI abnormalities (n = 8)]. All 42 biopsies were abnormal: IM in 28/42 (66.7%) and non-specific myopathic changes in 14/42 (33.3%), indicating 28/423 (6.6%) SA patients had biopsy-proven IM compared with 18/1253 (1.4%) of the ASCS cohort. IM prompted use of immunomodulatory therapy, with improved muscle power in all cases. CONCLUSION: Biopsy-proven muscle involvement was identified in 9.9% of screened SSc patients, and detection of IM increased by ∼4.5-fold compared with routine care, enabling timely treatment and avoiding unnecessary, potentially harmful immunosuppression in non-inflammatory myopathy.
引用
- Bhushan V, Limaye V, Hansen D, et al. Evaluation of a screening algorithm to detect systemic sclerosis-related myopathy. Rheumatology (Oxford). 2026. PMID: 41604308. doi:10.1093/rheumatology/keaf688
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。